Lin Shu-Wen, Lin Chun-Jung, Yang Jyh-Chin
a Graduate Institute of Clinical Pharmacy, College of Medicine , National Taiwan University , Taipei , Taiwan.
b School of Pharmacy, College of Medicine , National Taiwan University , Taipei , Taiwan.
Expert Opin Pharmacother. 2017 Aug;18(12):1269-1277. doi: 10.1080/14656566.2017.1353079. Epub 2017 Jul 27.
Rifamycin SV MMX®, a non-absorbable rifamycin antibiotic formulated using the multi-matrix system, was designed to exhibit its pharmacological action on the distal small intestine and colon. Its clinical efficacy and safety profile in the treatment of traveler's diarrhea were evaluated in several clinical studies. Areas covered: This review summarizes all available evidence regarding clinical trials of the efficacy and safety profile of rifamycin SV MMX for the treatment of traveler's diarrhea. Expert opinion: Rifamycin SV MMX demonstrated an excellent pharmacokinetic profile with decreased systemic toxicity similar to rifaximin. In phase II and phase III clinical trials, concerns have been raised regarding the medicine's efficacy in terms of the time to last unformed stool and cure rate compared to current recommended antibiotics in the treatment of acute diarrhea caused by diarrheagenic Escherichia coli and invasive pathogens. The significance of the increase in MICs after the use of rifamycin SV MMX warrants further examination.
利福霉素SV MMX®是一种采用多基质系统配制的不可吸收性利福霉素抗生素，旨在对小肠远端和结肠发挥其药理作用。在多项临床研究中评估了其治疗旅行者腹泻的临床疗效和安全性。涵盖领域：本综述总结了关于利福霉素SV MMX治疗旅行者腹泻的疗效和安全性概况的所有现有临床试验证据。专家意见：利福霉素SV MMX表现出优异的药代动力学特征，全身毒性降低，类似于利福昔明。在II期和III期临床试验中，与目前推荐的用于治疗由致泻性大肠杆菌和侵袭性病原体引起的急性腹泻的抗生素相比，该药在至最后一次不成形粪便的时间和治愈率方面的疗效引发了关注。使用利福霉素SV MMX后MIC增加的意义值得进一步研究。
